Format

Send to

Choose Destination
J Clin Oncol. 2009 Jun 1;27(16):2645-52. doi: 10.1200/JCO.2008.19.1106. Epub 2009 Apr 13.

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

Author information

1
Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Warren G Magnuson Clinical Center, NIH, Bethesda, MD, USA.

Abstract

PURPOSE:

High-dose interleukin-2 (IL-2) induces durable therapeutic responses in a small subset of patients with metastatic melanoma and renal cell carcinoma, but simple pretreatment predictors of response have not been identified.

PATIENTS AND METHODS:

To identify predictive biomarkers of clinical response, sera from patients treated with high-dose IL-2 were collected for analysis using a customized, multiplex antibody-targeted protein array platform that surveyed expression of soluble factors associated with tumor immunobiology. Soluble factors associated with clinical responses were analyzed using a multivariate permutation test, and survival outcomes were determined using Kaplan-Meier and log-rank tests.

RESULTS:

A training set from 10 patients identified 68 potentially relevant soluble factors that were then tested in an independent validation set of 49 patients. Class comparison revealed a cluster of 11 biomarkers that were associated with therapeutic outcome. Vascular endothelial growth factor (VEGF) and fibronectin were identified as independent predictors of response. In particular, high levels of these proteins were correlated with lack of clinical response and decreased overall survival.

CONCLUSION:

Serum VEGF and fibronectin are easily measured pretreatment biomarkers that could serve to exclude patients unlikely to respond to IL-2 therapy.

PMID:
19364969
PMCID:
PMC2689845
DOI:
10.1200/JCO.2008.19.1106
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center